-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The American Institute of Clinical and Economic Evaluation (ICER) stated in a draft report released on May 5 that Biogen’s high-profile Alzheimer’s treatment drug aducanumab, due to “insufficient evidence” of benefit, The cost of the drug should be as low as US$2,500 per year to be considered cost-effective.
The American Institute of Clinical and Economic Evaluation (ICER) stated in a draft report released on May 5 that Biogen’s high-profile Alzheimer’s treatment drug aducanumab, due to “insufficient evidence” of benefit, The cost of the drug should be as low as US$2,500 per year to be considered cost-effective.
Data source: ICER draft report
Bojian stated in a statement issued on May 6 that the draft report “underestimated the possible overall value of aducanumab and did not accurately reflect the potential benefits of treating older elderly people.
But despite this, there are still different opinions on whether aducanumab is indeed a breakthrough drug.
weixin.
If only successful trials are considered, ICER believes that the annual price of aducanumab may rise to between US$11,100 and US$23,100.
After a three-month delay, the FDA plans to make a decision on aducanumab on June 7.
weixin.
qq.
com/s?__biz=MzA5MDAyNjQxMw==&mid=2650398697&idx=1&sn=52acbd6e0f519ea402096e6cf6aa07ed&chksm=881c872bbf6b0e3d5dc90bb81c1f7c9c69a0593ff8cc9ca68343c11bdc8e864814191fda8ee2&scene=21#wechat_redirect">[FDA postpones the decision to approve Biogen Alzheimer's medicine on January 30, 2021]
